{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:33:55Z","timestamp":1794472435818,"version":"4.9.1"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.critrevonc.2023.104224","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T21:31:57Z","timestamp":1704835917000},"page":"104224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts\u2019 position paper"],"prefix":"10.1016","volume":"194","author":[{"given":"Matteo","family":"Fassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Angerilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6477-3182","authenticated-orcid":false,"given":"Federica","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2023.104224_bib1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104224_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104224_bib3","article-title":"The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization","volume":"11","author":"Angerilli","year":"2021","journal-title":"Diagn. (Basel, Switz. )"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104224_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.32074\/1591-951X-859","article-title":"FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice","volume":"115","author":"Angerilli","year":"2023","journal-title":"Pathologica"},{"key":"10.1016\/j.critrevonc.2023.104224_bib5","unstructured":"Anon. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pemazyre."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104224_bib6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104224_bib7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.annonc.2021.04.012","article-title":"Practical considerations in screening for genetic alterations in cholangiocarcinoma","volume":"32","author":"Bekaii-Saab","year":"2021","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104224_bib8","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines\u00ae Insights: Biliary Tract Cancers, Version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104224_bib9","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104224_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122977","article-title":"Quality Assessment of Gallbladder Cancer Pathology Reports: A Dutch Nationwide Study","volume":"13","author":"de Bitter","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104224_bib11","article-title":"Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients","volume":"6","author":"de Bitter","year":"2022","journal-title":"NPJ Precis Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2023.104224_bib12","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1200\/JCO.2019.37.15_suppl.4084","article-title":"Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations","volume":"37","author":"Boileve","year":"2019","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104224_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543784.2021.1896703","article-title":"Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers","volume":"30","author":"Boil\u00e8ve","year":"2021","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MOG.0000000000000171","article-title":"Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma","volume":"31","author":"Borad","year":"2015","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104224_bib15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104224_bib16","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.21037\/tlcr-20-297","article-title":"Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists","volume":"9","author":"Brcic","year":"2020","journal-title":"Transl. lung Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/his.13520","article-title":"Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"73","author":"Burt","year":"2018","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104224_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12050750","article-title":"FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint","volume":"12","author":"Cappello","year":"2022","journal-title":"J. Pers. Med"},{"issue":"13","key":"10.1016\/j.critrevonc.2023.104224_bib19","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1158\/1078-0432.CCR-21-4462","article-title":"FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation","volume":"28","author":"Casak","year":"2022","journal-title":"Clin. Cancer Res J. Am. Assoc. Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104224_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25081864","article-title":"Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors","volume":"25","author":"Chrzanowska","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41416-022-01824-4","article-title":"Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary","volume":"127","author":"Conway","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104224_bib22","article-title":"Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures","volume":"14","author":"EJCA","year":"2021","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104224_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49860-0","article-title":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","volume":"9","author":"Ettrich","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104224_bib24","first-page":"1","article-title":"Tumor mutation burden: From comprehensive mutational screening to the clinic","volume":"19","author":"Galuppini","year":"2019","journal-title":"Cancer Cell Int [Internet]"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104224_bib25","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1038\/bjc.2013.610","article-title":"Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer","volume":"109","author":"Goeppert","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104224_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2023.104224_bib27","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","article-title":"Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements","volume":"40","author":"Goyal","year":"2022","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104224_bib29","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum. Pathol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104224_bib30","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104224_bib31","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/PAS.0000000000000670","article-title":"Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma","volume":"40","author":"Hayashi","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41379-021-00913-8","article-title":"NTRK insights: best practices for pathologists","volume":"35","author":"Hechtman","year":"2022","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104224_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09374-9","article-title":"Diagnosis of fusion genes using targeted RNA sequencing","volume":"10","author":"Heyer","year":"2019","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104224_bib34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"24","key":"10.1016\/j.critrevonc.2023.104224_bib35","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2023.104224_bib36","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1200\/JCO.2019.37.15_suppl.4087","article-title":"Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH)","volume":"37","author":"Javle","year":"2019","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104224_bib37","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104224_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10391","key":"10.1016\/j.critrevonc.2023.104224_bib39","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet (Lond., Engl. )"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.104224_bib40","first-page":"7","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int. J. Int Assoc. Study Liver"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib41","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104224_bib42","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.humpath.2011.12.007","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma","volume":"43","author":"Kipp","year":"2012","journal-title":"Hum. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104224_bib43","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/hep.25595","article-title":"Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes","volume":"55","author":"Komuta","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib44","first-page":"228","article-title":"Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc","volume":"34","author":"Kr\u00e4mer","year":"2023","journal-title":"Med. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104224_bib45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.path.2018.02.005","article-title":"Cholangiocarcinoma","volume":"11","author":"Krasinskas","year":"2018","journal-title":"Surg. Pathol. Clin."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104224_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104224_bib47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104224_bib48","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104224_bib49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"26","key":"10.1016\/j.critrevonc.2023.104224_bib50","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1200\/JCO.19.01479","article-title":"Ethical framework for including research biopsies in oncology clinical trials: American Society of Clinical Oncology Research Statement","volume":"37","author":"Levit","year":"2019","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104224_bib51","first-page":"1163","article-title":"Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features","volume":"27","author":"Liau","year":"2014","journal-title":"Mod. Pathol. J. U. S. Can. Acad. Pathol. Inc."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104224_bib52","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/2159-8290.CD-21-1640","article-title":"Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma","volume":"12","author":"Lin","year":"2022","journal-title":"Cancer Discov."},{"issue":"17","key":"10.1016\/j.critrevonc.2023.104224_bib53","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104224_bib54","first-page":"1","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2019","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib55","doi-asserted-by":"crossref","DOI":"10.1177\/1073274817729245","article-title":"Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"24","author":"Massarweh","year":"2017","journal-title":"Cancer Control"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104224_bib56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis","volume":"149","author":"Mavros","year":"2014","journal-title":"JAMA Surg."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104224_bib57","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol."},{"issue":"17_suppl","key":"10.1016\/j.critrevonc.2023.104224_bib58","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104224_bib59","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/fon-2020-0726","article-title":"Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma","volume":"17","author":"Merz","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2023.104224_bib60","unstructured":"Ministero della Salute. Potenziamento dei test di Next-Generation Sequencing per la profilazione genomica del colangiocarcinoma (GU n.80 del 4\u20134-2023) [Internet]. 2023;(6th March). Available from: http:\/\/www.salute.gov.it\/imgs\/C_17_pagineAree_4588_listaFile_itemName_0_file.pdf."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104224_bib61","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2017.01.010","article-title":"Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity","volume":"66","author":"Moeini","year":"2017","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104224_bib62","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"key":"10.1016\/j.critrevonc.2023.104224_bib63","unstructured":"Nagtegaal I., Arends M.J., Odze D., Lam A. WHO classification of Tumours Editorial Board. Digestive System Tumours [Internet]. 5th ed. Ly. 2019. Available from: http:\/\/publications.iarc.fr\/579."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104224_bib64","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104224_bib65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4254\/wjh.v2.i12.419","article-title":"Pathological classification of intrahepatic cholangiocarcinoma based on a new concept","volume":"2","author":"Nakanuma","year":"2010","journal-title":"World J. Hepatol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104224_bib66","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104224_bib67","article-title":"Feasibility of Comprehensive Genomic Profiling (CGP) in real-life clinical practice","volume":"13","author":"Nibid","year":"2023","journal-title":"Diagnostic"},{"key":"10.1016\/j.critrevonc.2023.104224_bib68","unstructured":"No Title [Internet]. [cited 2023a Jun 18];Available from: https:\/\/www.foundationmedicine.com\/test\/foundationone-liquid-cdx."},{"key":"10.1016\/j.critrevonc.2023.104224_bib69","unstructured":"No Title [Internet]. [cited 2023b Jun 18];Available from: https:\/\/www.guardantcomplete.com\/guardant-portfolio\/cdx."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100505","article-title":"Role of molecular genetics in the clinical management of cholangiocarcinoma","volume":"7","author":"Normanno","year":"2022","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104224_bib71","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14737140.2020.1807333","article-title":"Cholangiocarcinoma: investigations into pathway-targeted therapies","volume":"20","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2023.104224_bib72","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1016\/j.annonc.2022.07.084","article-title":"56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)","volume":"33","author":"Oh","year":"2022","journal-title":"Ann. Oncol. [Internet"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104224_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104224_bib74","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104224_bib75","first-page":"S1461","article-title":"76MO Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f\/r), FGFR inhibitor (FGFRi)-na\u00efve cholangiocarcinoma (CCA): ReFocus trial. Ann Oncol [Internet","volume":"33","author":"Park","year":"2022"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104224_bib76","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104224_bib77","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/1078-0432.CCR-22-2036","article-title":"FDA approval summary: pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib78","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00428-022-03343-2","article-title":"Expert opinion on NSCLC small specimen biomarker testing - Part 1: tissue collection and management","volume":"481","author":"Penault-Llorca","year":"2022","journal-title":"Virchows Arch."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104224_bib79","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5114\/ceh.2019.85166","article-title":"Epidemiology of gallbladder cancer","volume":"5","author":"Rawla","year":"2019","journal-title":"Clin. Exp. Hepatol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104224_bib80","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jmoldx.2017.05.006","article-title":"Validation of a Targeted RNA sequencing assay for kinase fusion detection in solid tumors","volume":"19","author":"Reeser","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2023.104224_bib81","unstructured":"Regime di rimborsabilita\u2019 e prezzo del medicinale per uso umano \"Pemazyre\". (Determina n. 377\/2022). 2022;10\u20133."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104224_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000446","article-title":"Precision oncology: separating the wheat from the chaff","volume":"3","author":"Remon","year":"2018","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104224_bib83","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104224_bib84","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2022.02.013","article-title":"Prognostic impact of FGFR2\/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study","volume":"166","author":"Rizzato","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104224_bib85","article-title":"IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib86","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104224_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100570","article-title":"How to read a next-generation sequencing report-what oncologists need to know","volume":"7","author":"Schmid","year":"2022","journal-title":"ESMO Open"},{"issue":"37","key":"10.1016\/j.critrevonc.2023.104224_bib88","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/EDBK_174176","article-title":"Precision oncology: who, how, what, when, and when not?","author":"Schwartzberg","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. B [Internet]"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104224_bib89","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104224_bib90","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.18632\/oncotarget.1943","article-title":"Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups","volume":"5","author":"Simbolo","year":"2014","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104224_bib91","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jhbp.62","article-title":"Roles of liver fluke infection as risk factor for cholangiocarcinoma","volume":"21","author":"Sithithaworn","year":"2014","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104224_bib92","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.104224_bib93","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","author":"Subbiah","year":"2023","journal-title":"Cancer Discov. [Internet]"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104224_bib94","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104224_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2011.10.017","article-title":"The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group","volume":"76","author":"Thunnissen","year":"2012","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104224_bib96","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamasurg.2020.1973","article-title":"Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches","volume":"155","author":"Tsilimigras","year":"2020","journal-title":"JAMA Surg."},{"issue":"14","key":"10.1016\/j.critrevonc.2023.104224_bib97","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"10272","key":"10.1016\/j.critrevonc.2023.104224_bib98","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet (Lond., Engl. )"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104224_bib99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/PDM.0b013e31814b8866","article-title":"Effects of processing delay, formalin fixation, and immunohistochemistry on RNA Recovery From Formalin-fixed Paraffin-embedded Tissue Sections","volume":"17","author":"van Maldegem","year":"2008","journal-title":"Diagn. Mol. Pathol. Am. J. Surg. Pathol. Part B"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104224_bib100","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMra1303917","article-title":"Cancer of unknown primary site","volume":"371","author":"Varadhachary","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2023.104224_bib101","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/j.annonc.2022.04.443","article-title":"O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann. Oncol. [Internet"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104224_bib102","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104224_bib103","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104224_bib104","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2023.104224_bib105","first-page":"9","article-title":"Correlation between TMB and MSI in patients with solid tumors","volume":"38","author":"ZHAO","year":"2020","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104224_bib106","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823003128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823003128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:55:36Z","timestamp":1760903736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823003128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":106,"alternative-id":["S1040842823003128"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104224","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts\u2019 position paper","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104224"}}